Prelude therapeutics announces first quarter 2022 financial results and operations update

Prelude remains on track for clinical data readouts and next steps for the prmt5 program, mcl1 inhibitor prt1419, and cdk9 inhibitor prt2527 in 2h2022

PRLD Ratings Summary

PRLD Quant Ranking